Differentiation between pathologic and physiologic left ventricular hypertrophy by tissue doppler assessment of long-axis function in patients with hypertrophic cardiomyopathy or systemic hypertension and in athletes

Dragos Vinereanu, Nicolae Florescu, Nicholas Sculthorpe, Ann C. Tweddel, Michael R. Stephens, Alan G. Fraser*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

278 Citations (Scopus)

Abstract

To identify new echocardiographic indexes of long-axis function that might differentiate between pathologic and physiologic left ventricular (LV) hypertrophy, we compared 60 subjects with different types of LV hypertrophy (group I: 15 patients with hypertrophic cardiomyopathy, group II: 15 patients with systemic hypertension, and group III: 30 athletes) with 20 normal subjects (group IV). The peak velocities of mitral annular motion at 4 sites were measured from the apex by tissue Doppler echocardiography. There were no differences in mean age and global ejection fraction between groups. Groups I and II had lower long-axis systolic and early diastolic velocities than the athletes (p <0.01) for all 4 sites. The best differentiation of pathologic from physiologic hypertrophy was provided by a mean systolic annular velocity <9 cm/s (sensitivity 87%, specificity 97%). Heterogeneity of annular velocities discriminated between group I and group II. Thus, long-axis systolic and early diastolic velocities are decreased in patients with pathologic hypertrophy, but preserved in athletes. These simple new echocardiographic parameters can differentiate between pathologic and physiologic hypertrophy.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalThe American Journal of Cardiology
Volume88
Issue number1
DOIs
Publication statusPublished - 1 Jul 2001
Externally publishedYes

Fingerprint

Dive into the research topics of 'Differentiation between pathologic and physiologic left ventricular hypertrophy by tissue doppler assessment of long-axis function in patients with hypertrophic cardiomyopathy or systemic hypertension and in athletes'. Together they form a unique fingerprint.

Cite this